Pietenpol Named Vice President for Research at Vanderbilt University

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JENNIFER PIETENPOL was named executive vice president for research at Vanderbilt University Medical Center, effective May 1.

Pietenpol will continue to serve as director of the Vanderbilt-Ingram Cancer Center. She is also the B.F. Byrd Jr. Professor of Oncology and a professor of biochemistry, cancer biology and otolaryngology.

According to Vanderbilt, Pietenpol will assume a portion of the responsibilities held by Lawrence Marnett, associate vice chancellor for research and senior associate dean for biomedical sciences. Marnett was named dean of basic sciences in the School of Medicine for Vanderbilt University.

In this role, Marnett will oversee the basic science departments, centers and institutes that are remaining with the university after the legal separation of the university and the medical center.

As executive vice president for research, Pietenpol will support the basic science programs in clinical departments, centers and institutes that will be housed in new VUMC. She will be responsible for leading the infrastructure that will advance much of the medical center’s basic research enterprise.

As director of VICC, Pietenpol has successfully renewed Vanderbilt-Ingram’s NCI designation as a comprehensive cancer center twice with exceptional merit ratings.

She has served on the Institute of Medicine’s National Cancer Policy Forum. In 2008, she was appointed by President George W. Bush to the National Cancer Advisory Board.

She was a member of the board of directors of the American Association for Cancer Research, and serves on numerous other cancer-related scientific advisory boards including the Blue Ribbon Panel to advise the vice president’s National Cancer Moonshot Initiative.

In 2012, she was elected as a fellow of the American Association for the Advancement of Science. She has received numerous honors for her research, most recently the Medical Research Advancement Award from the T.J. Martell Foundation.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login